Oral LSD Formulation Meets Phase III Endpoints in Anxiety and Depression Trials
Source Summary
DT120, an orally disintegrating tablet formulation of LSD, met primary endpoints in phase III clinical trials for generalized anxiety disorder and major depressive disorder. The investigational psychedelic drug demonstrated efficacy in both conditions in the completed trials.
Why it matters
Meeting phase III endpoints represents a significant milestone in the clinical development of a psychedelic treatment for common mental health disorders, potentially advancing a new therapeutic approach.
